Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidaemia: a systematic review and meta-analysis

Nirmala, Nanguneri; Avendano, Esther E; Morin, Rebecca A.

doi:10.1080/23744235.2021.1982140

Cited by 3 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As ezetimibe does not interact with CYP3A4 and therefore is not associated with drug-drug interactions with HAART, it should be considered as a treatment option in PLHIV with statin intolerance, or as an additional therapy in those who already receive the maximum indicated statin dose and do not reach LDL therapeutic targets. Furthermore, the results of a recent meta-analysis of 13 randomized controlled trials and single-arm trials comparing rosuvastatin plus ezetimibe versus rosuvastatin monotherapy showed significant reductions in LDL (−23.89 mg/dL), TC (−26.17 mg/dL), and TG levels (−18.57 mg/dL), but no reduction in HDL levels with ezetimibe [187]. Meanwhile, other studies showed a mean decrease of −18.18 mg/dL versus −9 mg/dL in TC levels, a mean decrease of −11.16 mg/dL versus −3 mg/dL in TG levels, and a mean decrease of −17.46 mg/dL versus −9.5 mg/dL in non-HDL levels [150].…”

Section: Ezetimibementioning

confidence: 99%

Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas

Papantoniou,

Arvanitakis,

Markakis

et al. 2024

Life

View full text Add to dashboard Cite

Infections with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) represent one of the greatest health burdens worldwide. The complex pathophysiological pathways that link highly active antiretroviral therapy (HAART) and HIV infection per se with dyslipidemia make the management of lipid disorders and the subsequent increase in cardiovascular risk essential for the treatment of people living with HIV (PLHIV). Amongst HAART regimens, darunavir and atazanavir, tenofovir disoproxil fumarate, nevirapine, rilpivirine, and especially integrase inhibitors have demonstrated the most favorable lipid profile, emerging as sustainable options in HAART substitution. To this day, statins remain the cornerstone pharmacotherapy for dyslipidemia in PLHIV, although important drug–drug interactions with different HAART agents should be taken into account upon treatment initiation. For those intolerant or not meeting therapeutic goals, the addition of ezetimibe, PCSK9, bempedoic acid, fibrates, or fish oils should also be considered. This review summarizes the current literature on the multifactorial etiology and intricate pathophysiology of hyperlipidemia in PLHIV, with an emphasis on the role of different HAART agents, while also providing valuable insights into potential switching strategies and therapeutic options.

show abstract

Section: Ezetimibementioning

confidence: 99%

Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas

Papantoniou,

Arvanitakis,

Markakis

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

A deeper dive into the REPRIEVE trial and the potential role of inflammation in residual risk

Kalra

2023

Journal of Clinical Lipidology

View full text Add to dashboard Cite

Pitavastatin in the Prevention of Cardiovascular Disease in People Living with HIV: A Review

Whiteson,

Drogy,

Eickel

et al. 2024

Cardiology in Review

View full text Add to dashboard Cite

HIV is associated with a wide array of pathophysiologic mechanisms that ultimately contribute to mortality. While HIV is traditionally known as a disease that attacks the immune system, it is now established that infection with HIV can cause cardiovascular disease (CVD). Through inflammation, atherogenesis, interactions with antiretroviral therapy/highly-active antiretroviral therapy (ART/HAART), and other mechanisms, HIV is an independent risk factor for the development of CVD. The treatment of the CVD risks associated with HIV is complicated, especially due to interactions with hyperlipidemic drugs and ART/HAART. There is a prompt need for a drug (or drug class) that is known to reduce the risk of CVD, specifically in people living with HIV. Recently, the randomized trial to prevent vascular events in HIV trial evaluated the usage of pitavastatin in preventing major cardiac events in people with HIV, showing a significant reduction in cardiac events among those taking the therapeutic. In this review, we evaluate the mechanisms by which HIV contributes to CVD, and the randomized trial to prevent vascular events in HIV trial, and postulate about future directions of the drug in treating people living with HIV.

show abstract

Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidaemia: a systematic review and meta-analysis

Cited by 3 publications

References 31 publications

Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas

Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas

A deeper dive into the REPRIEVE trial and the potential role of inflammation in residual risk

Pitavastatin in the Prevention of Cardiovascular Disease in People Living with HIV: A Review

Contact Info

Product

Resources

About